Roche Signs First In-licensing Deal In Korea With DigitalBiotech For Alzheimer's Disease Candidate
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's DigitalBiotech signed a research collaboration and license option agreement with Roche covering DigitalBiotech's proprietary RAGE antagonist program targeting Alzheimer's disease